{5-[3-(5-bromo-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidin]-1'-yl)isoxazol-5-yl]-2H-tetrazol-2-yl}acetic acid | 1241952-38-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: {5-[3-(5-bromo-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidin]-1'-yl)isoxazol-5-yl]-2H-tetrazol-2-yl}acetic acid
• 英文别名: 2-[5-[3-(5-Bromospiro[3,4-dihydrochromene-2,4'-piperidine]-1'-yl)-1,2-oxazol-5-yl]tetrazol-2-yl]acetic acid
• CAS: 1241952-38-4
• 化学式: C₁₉H₁₉BrN₆O₄
• 分子量: 475.302
• InChiKey: SIMRYXWGLGGGQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  119
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• [EN] NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE<br/>[FR] NOUVEAUX COMPOSÉS SPIRO UTILES COMME INHIBITEURS DE LA STÉAROYL-COENZYME A DELTA-9 DÉSATURASE
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2010094120A1

  公开（公告）日：2010-08-26

  Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

  结构式（I）的杂环芳香化合物相对于其他已知的硬脂酰辅酶A去饱和酶（SCD1）具有选择性抑制作用。本发明的化合物可用于预防和治疗与异常脂质合成和代谢相关的疾病，包括心血管疾病，如动脉粥样硬化；肥胖；糖尿病；神经系统疾病；代谢综合征；胰岛素抵抗；以及肝脂肪变性。
• NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE
  申请人：Lachance Nicolas

  公开号：US20110312952A1

  公开（公告）日：2011-12-22

  Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

  结构式（I）的杂环芳香化合物是选择性的硬脂酰辅酶A-Δ9-脱饱和酶（SCD1）抑制剂，相对于其他已知的硬脂酰辅酶A脱饱和酶。本发明的化合物对于预防和治疗与异常脂质合成和代谢相关的疾病非常有用，包括心血管疾病，如动脉粥样硬化；肥胖症；糖尿病；神经系统疾病；代谢综合征；胰岛素抵抗和肝脂肪变性。
• US9168248B2
  申请人：——

  公开号：US9168248B2

  公开（公告）日：2015-10-27